|
1
|
Rogers HW, Weinstock MA, Harris AR,
Hinckley MR, Feldman SR, Fleischer AB and Coldiron BM: Incidence
estimate of nonmelanoma skin cancer in the United States, 2006.
Arch Dermatol. 146:283–287. 2010.PubMed/NCBI
|
|
2
|
Christenson LJ, Borrowman TA, Vachon CM,
Tollefson MM, Otley CC, Weaver AL and Roenigk RK: Incidence of
basal cell and squamous cell carcinomas in a population younger
than 40 years. JAMA. 294:681–690. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen JG, Fleischer AB Jr, Smith ED,
Kancler C, Goldman ND, Williford PM and Feldman SR: Cost of
nonmelanoma skin cancer treatment in the United States. Dermatol
Surg. 27:1035–1038. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rowe DE, Carroll RJ and Day CL Jr:
Prognostic factors for local recurrence, metastasis and survival
rates in squamous cell carcinoma of the skin, ear and lip.
Implications for treatment modality selection. J Am Acad Dermatol.
26:976–990. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Comprehensive Cancer Network
Guidelines of Cancers by Site Available online. http://www.nccn.org/professionals/physicianAccessed.
October 24–2014
|
|
6
|
Tanvetyanon T, Padhya T, McCaffrey J, Kish
JA, Deconti RC, Trotti A and Rao NG: Postoperative concurrent
chemotherapy and radiotherapy for high-risk cutaneous squamous cell
carcinoma of the head and neck. Head Neck. 37:840–845. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bernier J, Domenge C, Ozsahin M,
Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P,
Rolland F, Bolla M, et al: Postoperative irradiation with or
without concomitant chemotherapy for locally advanced head and neck
cancer. N Engl J Med. 350:1945–1952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jarkowski A III, Hare R, Loud P, Skitzki
JJ, Kane JM III, May KS, Zeitouni NC, Nestico J, Vona KL, Groman A
and Khushalani NI: Systemic therapy in advanced cutaneous squamous
cell carcinoma (CSCC): The Roswell Park experience and a review of
the literature. Am J Clin Oncol. 2014.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mecca C, Ponzetti A, Caliendo V, Ciuffreda
L and Lista P: Complete response of metastatic cutaneous squamous
cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol.
22:758–761. 2012.PubMed/NCBI
|
|
10
|
Nakamura K, Okuyama R, Saida T and Uhara
H: Platinum and anthracycline therapy for advanced cutaneous
squamous cell carcinoma. Int J Clin Oncol. 18:506–509. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
DeConti RC: Chemotherapy of squamous cell
carcinoma of the skin. Semin Oncol. 39:145–149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maubec E, Duvillard P, Velasco V, Crickx B
and Avril MF: Immunohistochemical analysis of EGFR and HER-2 in
patients with metastatic squamous cell carcinoma of the skin.
Anticancer Res. 25:1205–1210. 2005.PubMed/NCBI
|
|
14
|
Kalyankrishna S and Grandis JR: Epidermal
growth factor receptor biology in head and neck cancer. J Clin
Oncol. 24:2666–2672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ciardiello F and Tortora G: A novel
approach in the treatment of cancer: Targeting the epidermal growth
factor receptor. Clin Cancer Res. 7:2958–2970. 2001.PubMed/NCBI
|
|
16
|
Arteaga C: Targeting HER1/EGFR: A
molecular approach to cancer therapy. Semin Oncol. 30(3 Suppl 7):
3–14. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uribe P and Gonzalez S: Epidermal growth
factor receptor (EGFR) and squamous cell carcinoma of the skin:
Molecular bases for EGFR-targeted therapy. Pathol Res Pract.
207:337–342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim S, Eleff M and Nicolaou N: Cetuximab
as primary treatment for cutaneous squamous cell carcinoma to the
neck. Head Neck. 33:286–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Laimer K, Spizzo G, Gastl G, Obrist P,
Brunhuber T, Fong D, Barbieri V, Jank S, Doppler W, Rasse M and
Norer B: High EGFR expression predicts poor prognosis in patients
with squamous cell carcinoma of the oral cavity and oropharynx: A
TMA-based immunohistochemical analysis. Oral Oncol. 43:193–198.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang AR, Wu HG, Park CI, Jun YK and Kim
CW: Expression of epidermal growth factor receptor and cyclin D1 in
pretreatment biopsies as a predictive factor of radiotherapy
efficacy in early glottic cancer. Head Neck. 30:852–857. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kearsley JH, Furlong KL, Cooke RA and
Waters MJ: An immunohistochemical assessment of cellular
proliferation markers in head and neck squamous cell cancers. Br J
Cancer. 61:821–827. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bentzen SM, Atasoy BM, Daley FM, Dische S,
Richman PI, Saunders MI, Trott KR and Wilson GD: Epidermal growth
factor receptor expression in pretreatment biopsies from head and
neck squamous cell carcinoma as a predictive factor for a benefit
from accelerated radiation therapy in a randomized controlled
trial. J Clin Oncol. 23:5560–5567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pedicini P, Nappi A, Strigari L,
Jereczek-Fossa BA, Alterio D, Cremonesi M, Botta F, Vischioni B,
Caivano R, Fiorentino A, et al: Correlation between EGFR expression
and accelerated proliferation during radiotherapy of head and neck
squamous cell carcinoma. Radiat Oncol. 7:1432012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pierceall WE, Goldberg LH, Tainsky MA,
Mukhopadhyay T and Ananthaswamy HN: Ras gene mutation and
amplification in human nonmelanoma skin cancers. Mol Carcinog.
4:196–202. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khan SG, Mohan RR, Katiyar SK, Wood GS,
Bickers DR, Mukhtar H and Agarwal R: Mutations in ras oncogenes:
Rare events in ultraviolet B radiation-induced mouse skin
tumorigenesis. Mol Carcinog. 15:96–103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mauerer A, Herschberger E, Dietmaier W,
Landthaler M and Hafner C: Low incidence of EGFR and HRAS mutations
in cutaneous squamous cell carcinomas of a German cohort. Exp
Dermatol. 20:848–850. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abidi A: Hedgehog signaling pathway: A
novel target for cancer therapy: Vismodegib, a promising
therapeutic option in treatment of basal cell carcinomas. Indian J
Pharmacol. 46:3–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Proctor AE, Thompson LA and O'Bryant CL:
An inhibitor of the Hedgehog signaling pathway in the treatment of
basal cell carcinoma. Ann Pharmacother. 48:99–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tietze JK, Pfob M, Eggert M, von Preußen
A, Mehraein Y, Ruzicka T and Herzinger T: A non-coding mutation in
the 5′ untranslated region of patched homologue 1 predisposes to
basal cell carcinoma. Exp Dermatol. 22:834–835. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salas Ruiz V, Alegre M, Garcés JR and Puig
L: Locally advanced and metastatic basal cell carcinoma: Molecular
pathways, treatment options and new targeted therapies. Expert Rev
Anticancer Ther. 14:741–749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pandolfi S and Stecca B: Cooperative
integration between HEDGEHOG-GLI signalling and other oncogenic
pathways: Implications for cancer therapy. Expert Rev Mol Med.
17:e52015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brechbiel J, Miller-Moslin K and Adjei AA:
Crosstalk between hedgehog and other signaling pathways as a basis
for combination therapies in cancer. Cancer Treat Rev. 40:750–759.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toll A, Salgado R, Yébenes M,
Martín-Ezquerra G, Gilaberte M, Baró T, Solé F, Alameda F, Espinet
B and Pujol RM: Epidermal growth factor receptor gene numerical
aberrations are frequent events in actinic keratoses and invasive
cutaneous squamous cell carcinomas. Exp Dermatol. 19:151–153. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Perri F, Longo F, Ionna F and Caponigro F:
Recent results of cetuximab use in the treatment of squamous cell
carcinoma of the head and neck. Onco Targets Ther. 2:243–250.
2009.PubMed/NCBI
|
|
35
|
Kalapurakal SJ, Malone J, Robbins KT,
Buescher L, Godwin J and Rao K: Cetuximab in refractory skin cancer
treatment. J Cancer. 3:257–261. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maubec E, Petrow P, Scheer-Senyarich I,
Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B,
Buffard V, et al: Phase II study of cetuximab as first-line
single-drug therapy in patients with unresectable squamous cell
carcinoma of the skin. J Clin Oncol. 29:3419–3426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bauman JE, Eaton KD and Martins RG:
Treatment of recurrent squamous cell carcinoma of the skin with
cetuximab. Arch Dermatol. 143:889–892. 2007.PubMed/NCBI
|
|
38
|
Suen JK, Bressler L, Shord SS, Warso M and
Villano JL: Cutaneous squamous cell carcinoma responding serially
to single-agent cetuximab. Anticancer Drugs. 18:827–829. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Preneau S, Rio E, Brocard A, Peuvrel L,
Nguyen JM, Quéreux G and Dreno B: Efficacy of cetuximab in the
treatment of squamous cell carcinoma. J Dermatolog Treat.
25:424–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Samstein RM, Ho AL, Lee NY and Barker CA:
Locally advanced and unresectable cutaneous squamous cell
carcinoma: Outcomes of concurrent cetuximab and radiotherapy. J
Skin Cancer. 2014:2845822014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Falivene S, Giugliano FM, Grimaldi AM, Di
Franco R, Toledo D, Muto M, Cammarota F, Borzillo V, Ascierto PA
and Muto P: Tomotherapy concomitant with cetuximab, followed by
cetuximab as single-agent therapy for unresectable squamous cell
carcinoma of the skin: A case report. BMC Dermatol. 14:152014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Muller K and Meineke V: Radiation-induced
alterations in cytokine production by skin cells. Exp Hematol. 35(4
Suppl 1): S96–S104. 2007. View Article : Google Scholar
|
|
43
|
Segaert S and Van Cutsem E: Clinical
signs, pathophysiology and management of skin toxicity during
therapy with epidermal growth factor receptor inhibitors. Ann
Oncol. 16:1425–1433. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Busam KJ, Capodieci P, Motzer R, Kiehn T,
Phelan D and Halpern AC: Cutaneous side-effects in cancer patients
treated with the antiepidermal growth factor receptor antibody
C225. Br J Dermatol. 144:1169–1176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Perez-Soler R, Zou Y, Li T and Ling YH:
The phosphatase inhibitor menadione (vitamin K3) protects cells
from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res.
17:6766–6777. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bernier J, Bonner J, Vermorken JB,
Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R,
Robert C, et al: Consensus guidelines for the management of
radiation dermatitis and coexisting acne-like rash in patients
receiving radiotherapy plus EGFR inhibitors for the treatment of
squamous cell carcinoma of the head and neck. Ann Oncol.
19:142–149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Foote MC, McGrath M, Guminski A, Hughes
BG, Meakin J, Thomson D, Zarate D, Simpson F and Porceddu SV: Phase
II study of single-agent panitumumab in patients with incurable
cutaneous squamous cell carcinoma. Ann Oncol. 25:2047–2052. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Perez CA, Song H, Raez LE, Agulnik M,
Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY,
et al: Phase II study of gefitinib adaptive dose escalation to skin
toxicity in recurrent or metastatic squamous cell carcinoma of the
head and neck. Oral Oncol. 48:887–892. 2012. View Article : Google Scholar : PubMed/NCBI
|
